ITL announces today continued advances in its immunomonitoring key initiative. It was discovered that the manner in which tumor tissues are preserved and shipped affects the quality of immune data

New methods have been developed to preserve previous immune data in biopsy tissues from the time they are collected until time they are processed into slides.

A key component of this discovery is the need to standardize the methods for processing the tissues.

 ITL has now established a fully functional, state-of-the-art histology laboratory at its subsidiary in Phoenix,AZ to serve as a service center to process clinical biopsy specimens collected from patients all over the world.

Dr. Miriam Bloch, MD  a board certified pathologist has been appointed to head this laboratory.

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more